Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit
Daniel D Langleben1, Paul D Acton, Glenn Austin
1Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. langlebe@mail.med.upenn.edu
Unlabelled:
Methylphenidate (MPH) is an effective symptomatic treatment of attention deficit hyperactivity disorder (ADHD), but the mechanisms of its therapeutic action have not been fully elucidated. To address this issue, we assessed the effects of discontinuation of chronic MPH treatment on regional cerebral blood flow (rCBF) in ADHD patients.
Methods:
Twenty-two prepubescent boys with ADHD (age range, 8.2-11.5 y) and 7 healthy volunteers were studied with SPECT on and off MPH. Their rCBF data were automatically normalized to whole-brain counts and coregistered with standard anatomic space. rCBF changes were evaluated with statistical parametric mapping based on voxel-by-voxel ANOVA.
Results:
When the subjects were not taking MPH, rCBF was higher in the motor, premotor, and the anterior cingulate cortices (Brodmann's areas 4, 6, and 32).
Conclusion:
Brief discontinuation of MPH treatment is associated with increased motor and anterior cingulate cortical activity. Our findings suggest that MPH treatment modulates motor and anterior cingulate cortical activity directly or indirectly. Alternatively, our findings may be related to MPH withdrawal. These data provide novel information on the potential mechanisms of the therapeutic action of MPH. Furthermore, they are clinically relevant to the commonly occurring brief interruptions in MPH treatment.
Insights
Stopping methylphenidate (MPH) temporarily increases activity in motor and anterior cingulate areas for children with attention deficit hyperactivity disorder (ADHD). This suggests MPH directly affects these brain regions.
Area of Science:
- Neuroscience
- Pharmacology
- Pediatrics
Background:
- Methylphenidate (MPH) is a primary symptomatic treatment for attention deficit hyperactivity disorder (ADHD).
- The precise mechanisms underlying MPH's therapeutic effects remain incompletely understood.
- Investigating changes in brain activity upon MPH discontinuation may elucidate its mode of action.
Purpose of the Study:
- To examine the impact of discontinuing chronic methylphenidate (MPH) treatment on regional cerebral blood flow (rCBF) in boys with ADHD.
- To explore potential mechanisms of MPH's therapeutic action by observing brain activity changes after treatment cessation.
Main Methods:
- SPECT imaging was used to assess rCBF in 22 prepubescent boys with ADHD and 7 healthy controls.
- rCBF data were collected both while subjects were taking MPH and after a period of discontinuation.
- Statistical parametric mapping (SPM) was employed to analyze voxel-by-voxel rCBF changes.
Main Results:
- Discontinuation of MPH was associated with significantly higher rCBF in the motor cortex, premotor cortex, and anterior cingulate cortex (Brodmann's areas 4, 6, and 32).
- These findings indicate a direct or indirect modulatory effect of MPH on these specific cortical regions.
Conclusions:
- Brief cessation of MPH treatment leads to increased activity in motor and anterior cingulate cortical areas in ADHD patients.
- These observed changes suggest MPH directly influences motor and cingulate functions, or they may reflect withdrawal effects.
- The study provides new insights into MPH's therapeutic mechanisms and clinical relevance for treatment interruptions.
More Related Videos
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...


